Adolescent vaccines: Need special focus in India.

Abstract:

:WHO defines adolescence age between 10 to 19 years. In India, there are 243 million adolescents which constitute 21 per cent of the total population. The global burden of disease in adolescents (2011) reports that the total number of disability adjusted life years (DALYs) worldwide among adolescents were 230 million which constitutes 15.5% of total DALYs. The immunization is one of the most important, most beneficial and cost-effective disease prevention measures that can be provided for adolescents. The adolescent vaccination protects most of the world's adolescents from a number of infectious diseases that previously claimed millions of lives each year. In India, thousands of adolescents die and thousands are hospitalized every year due to communicable diseases that could have been prevented by vaccination. Main aims of adolescent vaccinations are: to boost immunity status that is waning after completion of primary immunization or absence of "natural" boosting due exposure to the particular disease. The recommendations for the immunization of adolescents are to improve vaccination coverage among them. The adolescent vaccinations also help in accelerate disease control or elimination effort. Improvement in adolescent immunization coverage in India, will require strengthening of health care delivery system and also require significant improvements in the health care functionaries ability and willingness to provide and deliver vaccines to adolescents.

journal_name

Hum Vaccin Immunother

authors

Verma R,Khanna P,Chawla S

doi

10.4161/hv.29757

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

2880-2

issue

12

eissn

2164-5515

issn

2164-554X

journal_volume

11

pub_type

杂志文章
  • A new therapeutic potential for cancers: One CAR with 2 different engines!

    abstract::Tumor cells escape from immune recognition by several mechanisms such as down-regulating of MHC class I molecules, losing of tumor antigens, etc. The purpose of cancer immunotherapy is to robust or reconstruct the capacity of the immune system to recognize and kill tumor cells by overwhelming the mechanisms by which t...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 信件

    doi:10.1080/21645515.2017.1314874

    authors: Sheikhi A,Jafarzadeh A

    更新日期:2017-08-03 00:00:00

  • Varicella vaccine strain infection in a non-immunocompromised patient. A case report and review of literature.

    abstract::Varicella live attenuated vaccine led to a significant reduction in morbidity and mortality from varicella zoster disease. Vaccine adverse effects are mostly mild. Immunosuppression is the main risk factor for severe varicella. Risk factors for disease following vaccination are less studied. We report a 12-month-old i...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1802976

    authors: Swed-Tobia R,Kassis I,Hanna S,Szwarcwort-Cohen M,Dovrat S,Dabaja-Younis H

    更新日期:2020-09-18 00:00:00

  • Generation and testing anti-influenza human monoclonal antibodies in a new humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO. IL-2Rγc KO. NOD).

    abstract::Pandemic outbreaks of influenza type A viruses have resulted in numerous fatalities around the globe. Since the conventional influenza vaccines (CIV) provide less than 20% protection for individuals with weak immune system, it has been considered that broadly cross-neutralizing antibodies may provide a better protecti...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1403703

    authors: Mendoza M,Ballesteros A,Qiu Q,Pow Sang L,Shashikumar S,Casares S,Brumeanu TD

    更新日期:2018-02-01 00:00:00

  • Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.

    abstract::The study of influenza virus evolution in humans has revealed a significant role of glycosylation profile alterations in the viral glycoproteins - hemagglutinin (HA) and neuraminidase (NA), in the emergence of both seasonal and pandemic strains. Viral antigenic drift can modify the number and location of glycosylation...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1377871

    authors: Cruz E,Cain J,Crossett B,Kayser V

    更新日期:2018-03-04 00:00:00

  • Pembrolizumab (Keytruda).

    abstract::The programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. Ligation of PD1 with its ligands PDL1 and PDL2 results in transduction of negative signals to T-cells. PD1 expression is an important mechanism contributing to the exhausted effector T-cell phenotype. The expression...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1199310

    authors: Kwok G,Yau TC,Chiu JW,Tse E,Kwong YL

    更新日期:2016-11-01 00:00:00

  • Dissecting the indirect effects caused by vaccines into the basic elements.

    abstract::Vaccination directly protects vaccinated individuals, but it also has the potential for indirectly protecting the unvaccinated in a population (herd protection). Unintended negative consequences such as the re-manifestation of infection, mainly expressed as age shifts, result from vaccination programs as well. We disc...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2015.1052196

    authors: Scarbrough Lefebvre CD,Terlinden A,Standaert B

    更新日期:2015-01-01 00:00:00

  • Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China.

    abstract:INTRODUCTION:Enterovirus A71(EV-A71)-associated hand, foot, and mouth disease (HFMD) has been reported worldwide, and poses a particularly heavy burden on patients, families, and society in China. Three Chinese companies have licensed inactivated EV-A71 vaccines, all of which have demonstrated good efficacy for prevent...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1581539

    authors: Wang X,An Z,Huo D,Jia L,Li J,Yang Y,Liang Z,Wang Q,Wang H

    更新日期:2019-01-01 00:00:00

  • Challenges to optimising uptake and delivery of a HPV vaccination programme for men who have sex with men.

    abstract::Human papillomavirus (HPV) vaccine programmes targeted at men who have sex with men (MSM) may reduce HPV-related disease burden among this at-risk group in countries where uptake of the vaccine among adolescent girls is sub-optimal and where adolescent boys are not routinely vaccinated. There are challenges to optimis...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1560783

    authors: Forster AS,Gilson R

    更新日期:2019-01-01 00:00:00

  • ReadyVax: A new mobile vaccine information app.

    abstract::Vaccine information of varying quality is available through many different sources. We describe the creation, release and utilization of ReadyVax, a new mobile smartphone app providing access to trustworthy, evidence-based vaccine information for a target audience of healthcare providers, pharmacists, and patients (in...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2016.1263779

    authors: Bednarczyk RA,Frew PM,Salmon DA,Whitney E,Omer SB

    更新日期:2017-05-04 00:00:00

  • Product review: avelumab, an anti-PD-L1 antibody.

    abstract::Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppression in the tumor mi...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2018.1551671

    authors: Collins JM,Gulley JL

    更新日期:2019-01-01 00:00:00

  • Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain).

    abstract::The objectives of this study were to estimate incidence density rates (IDR) of herpes zoster (HZ) and to analyze the association with sociodemographic characteristics and selected chronic medical conditions. The study cohort consisted of the adult population included in the Public Health System of the Autonomous Commu...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.28620

    authors: Esteban-Vasallo MD,Domínguez-Berjón MF,Gil-Prieto R,Astray-Mochales J,Gil de Miguel A

    更新日期:2014-01-01 00:00:00

  • Prospective randomized open-label comparative study of immunogenicity after subunit and polymeric subunit influenza vaccines administration among mothers and infants.

    abstract::Pregnant women are risk group for influenza infection. Results of new subunit vaccines application have not been studied enough. Prospective, randomized, open-label comparative study of subunit (Agrippal) and polymeric subunit (Grippol plus) vaccines. 42 pairs of mothers-infants were participated in the study. Protect...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1507585

    authors: Kostinov MP,Cherdantsev AP,Kuselman AI,Akhmatova NK,Kostinova AM,Deryabina EV,Demina EO,Kostinov AM

    更新日期:2018-01-01 00:00:00

  • The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority stud

    abstract::Immunogenicity and safety of ACWY-TT compared with licensed ACWY polysaccharide vaccine (MenPS) in healthy adults, and lot-to-lot consistency of three ACWY-TT lots were evaluated in a phase 3, open, controlled study. Adults aged 18-55 y were randomized to receive ACWY-TT (one of three lots) or MenPS. Serum bactericida...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/hv.20211

    authors: Dbaibo G,Macalalad N,Aplasca-De Los Reyes MR,Dimaano E,Bianco V,Baine Y,Miller J

    更新日期:2012-07-01 00:00:00

  • Timeliness of vaccination in infants followed by primary-care pediatricians in France.

    abstract::Vaccination status is more often evaluated by up-to-date vaccination coverage rather than timeliness of immunization. Delaying vaccination may be dangerous during infancy. The aim of this study was to identify the importance of potentially dangerous vaccination delay (previously defined) and determinants of these dela...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1409318

    authors: Bailly AC,Gras P,Lienhardt JF,Requillart JC,Vié-le-Sage F,Martinot A,Dubos F

    更新日期:2018-04-03 00:00:00

  • Recent developments in clinical trial designs for HIV vaccine research.

    abstract::HIV vaccine strategies are expected to be a crucial component for controlling the HIV epidemic. Despite the large spectrum of potential candidate vaccines for both prophylactic and therapeutic use, the overall development process of an efficacious HIV vaccine strategy is lengthy. The design of clinical trials and the ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2015.1011974

    authors: Richert L,Lhomme E,Fagard C,Lévy Y,Chêne G,Thiébaut R

    更新日期:2015-01-01 00:00:00

  • Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine in healthy toddlers: results from a phase I, randomized trial.

    abstract::As a stepping stone toward evaluation in infants, the safety and immunogenicity of an investigational 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (12vPHiD-CV) was assessed in toddlers. 12vPHiD-CV contains CRM197-conjugated capsular polysaccharides of serotypes 6A and 19A in a...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1810493

    authors: Horn M,Behre U,Traskine M,Dobbelaere K,Borys D

    更新日期:2020-11-11 00:00:00

  • The intentions to get vaccinated against influenza and actual vaccine uptake among diabetic patients in Ningbo, China: identifying motivators and barriers.

    abstract:BACKGROUND:Health authorities recommend influenza vaccination to diabetic patients. Nevertheless, the vaccination coverage of adults was low in China. This study aimed to estimate influenza vaccination intentions and actual uptake among diabetic patients in China and identify the motivators and barriers associated with...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1761201

    authors: Ye L,Fang T,Cui J,Zhu G,Ma R,Sun Y,Li P,Li H,Dong H,Xu G

    更新日期:2020-05-27 00:00:00

  • Facilitators and barriers for use of rotavirus vaccine amongst various stakeholders and its implications for Indian context - A systematic review.

    abstract::Background: We performed a systematic review to evaluate factors affecting uptake of rotavirus vaccine amongst physicians, parents and health system. Methods: We identified 15 studies that met the inclusion criteria from 790 screened studies published between Jan 2005 to Jan 2016. Results: Perceived severity of rotavi...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1489190

    authors: Apte A,Roy S,Bavdekar A,Juvekar S,Hirve S

    更新日期:2018-01-01 00:00:00

  • High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study.

    abstract::In patients undergoing immunotherapy, the quality of the immune response is reduced, which may negatively affect the efficacy of vaccination. This study was conducted in order to evaluate the efficacy of the hepatitis B virus (HBV) vaccine in patients using immunomodulators. Seronegative patients for HBV who were usin...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1574151

    authors: Haykir Solay A,Eser F

    更新日期:2019-01-01 00:00:00

  • Immunization services offered in Québec (Canada) pharmacies.

    abstract::Canadian Pharmacists are easy to reach. Although Québec pharmacists are not allowed to administer vaccines, they can: (1) promote vaccination, (2) counsel patients on vaccination, (3) sell vaccines and (4) provide vaccine administration by a nurse. Our objectives were to describe immunization services given in Québec ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.25186

    authors: Sauvageau C,Dubé E,Bradet R,Mondor M,Lavoie F,Moisan J

    更新日期:2013-09-01 00:00:00

  • Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.

    abstract::Rotavirus (RV) and norovirus (NoV) are the 2 leading causes of acute viral gastroenteritis worldwide. We have developed a non-live NoV and RV vaccine candidate consisting of NoV virus-like particles (VLPs) and recombinant polymeric RV VP6 protein produced in baculovirus-insect cell expression system. Both components h...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1099772

    authors: Blazevic V,Malm M,Arinobu D,Lappalainen S,Vesikari T

    更新日期:2016-03-03 00:00:00

  • Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.

    abstract::Current cancer immunotherapies predominantly rely on CD8(+) T cells to fight against tumors. However accumulative evidence showed that proinflammatory CD4(+) helper T cells are critical determinants of effective antitumor immunity. The utilization of universal tumor-reactive helper peptides from telomerase represents ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.23587

    authors: Adotévi O,Dosset M,Galaine J,Beziaud L,Godet Y,Borg C

    更新日期:2013-05-01 00:00:00

  • Mandatory influenza vaccination programs for health care personnel in NACHRI-associated children's hospitals vs. non-children's hospitals.

    abstract::We conducted a national study of children's hospitals and neighboring general medical-surgical hospitals to examine their employee vaccination policies. Survey questions addressed health care personnel (HCP) influenza vaccination policies for the 2009-2010 (seasonal, H1N1) and 2010-2011 (H1N1 + seasonal = combined) in...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.19613

    authors: Danziger P,Davis MM

    更新日期:2012-06-01 00:00:00

  • Influenza vaccine effectiveness assessment through sentinel virological data in three post-pandemic seasons.

    abstract::Influenza vaccination aims at reducing the incidence of serious disease, complications and death among those with the most risk of severe influenza disease. Influenza vaccine effectiveness (VE) through sentinel surveillance data from the PIDIRAC program (Daily Acute Respiratory Infection Surveillance of Catalonia) dur...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.36155

    authors: Torner N,Martínez A,Basile L,Marcos MA,Antón A,Mar Mosquera M,Isanta R,Cabezas C,Jané M,Domínguez A,Program Of Catalonia TP

    更新日期:2015-01-01 00:00:00

  • Achieving high HPV vaccine completion rates in a pediatric clinic population.

    abstract::Objective: To evaluate the efficacy of an intervention utilizing patient navigators (PNs) to 1) educate families on human papillomavirus (HPV) vaccination in a clinic setting and 2) provide personalized reminders for follow-up. Method: Families with 9-17 year-old children who had no record of completing the HPV vaccin...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1533778

    authors: Berenson AB,Rupp R,Dinehart EE,Cofie LE,Kuo YF,Hirth JM

    更新日期:2019-01-01 00:00:00

  • Effectiveness of human papillomavirus vaccination in young Japanese women: a retrospective multi-municipality study.

    abstract::In Japan, government support for human papillomavirus (HPV) vaccination began in November 2010. However, the mass media repeatedly reported on severe adverse events. The Japanese Ministry of Health, Labor and Welfare suspended proactive recommendations for HPV vaccines in June 2013. Japan's HPV vaccination rate droppe...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1817715

    authors: Tozawa-Ono A,Kamada M,Teramoto K,Hareyama H,Kodama S,Kasai T,Iwanari O,Koizumi T,Ozawa N,Suzuki M,Kinoshita K

    更新日期:2020-10-29 00:00:00

  • Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis.

    abstract::Tuberculosis (TB) is a significant cause of illness and death worldwide. Immunotherapy has been investigated in the treatment of TB. The purpose of this study was to perform a meta-analysis investigating the effectiveness of the M. vaccae vaccine. Medline, Cochrane, EMBASE, and Google Scholar were searched until Novem...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/21645515.2017.1335374

    authors: Huang CY,Hsieh WY

    更新日期:2017-09-02 00:00:00

  • Factors contributing to the immunogenicity of meningococcal conjugate vaccines.

    abstract::Various glycoprotein conjugate vaccines have been developed for the prevention of invasive meningococcal disease, having significant advantages over pure polysaccharide vaccines. One of the most important features of the conjugate vaccines is the induction of a T-cell dependent immune response, which enables both the ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1153206

    authors: Bröker M,Berti F,Costantino P

    更新日期:2016-07-02 00:00:00

  • Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al.

    abstract::Hollingsworth and Isturiz (1) have raised several questions about our earlier review of the use of pneumococcal conjugate (PCV) or polysaccharide (PPV) vaccine for older adults (i.e., ≥65 y of age). (2) They begin by citing two metaanalyses published in 2009 and 2013 that concluded that prevention of pneumococcal pneu...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 评论,信件

    doi:10.4161/hv.26422

    authors: Fedson DS

    更新日期:2014-01-01 00:00:00

  • Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety.

    abstract::Post licensure surveillance of adverse events following immunization (AEFI) is a fundamental activity to improve safety and maintain public confidence in vaccines.   Since 2011, the Liguria Region has been involved in the inter-regional project of post-marketing surveillance of AEFI, coordinated by the Italian Medicin...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.34360

    authors: Alicino C,Merlano C,Zappettini S,Schiaffino S,Della Luna G,Accardo C,Gasparini R,Durando P,Icardi G

    更新日期:2015-01-01 00:00:00